Compounds > gemcitabine
Page last updated: 2024-08-24

gemcitabine and celastrol

gemcitabine has been researched along with celastrol in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Cheng, Z; Han, B; Jia, G; Jiang, H; Liu, J; Pan, S; Sun, B; Wang, Y; Zhou, H; Zhou, Y1
Jiang, Z; Liu, Y; Tao, L; Zhao, Y1

Other Studies

3 other study(ies) available for gemcitabine and celastrol

ArticleYear
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells.
    PloS one, 2012, Volume: 7, Issue:8

    Topics: Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms; Pentacyclic Triterpenes; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Triterpenes

2012
Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2021, Volume: 147

    Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Repair; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Pentacyclic Triterpenes; Tumor Suppressor p53-Binding Protein 1

2021